Clinical Effectiveness and Safety Comparison between Reduced Rivaroxaban Dose and Dual Antiplatelet Therapy for Nonvalvular Atrial Fibrillation Patients Following Percutaneous Left Atrial Appendage Closure: A Prospective Observational Study

作者：Xiaoye Li, Qinchun Jin, Yao Yao, Xiaochun Zhang, Qianzhou Lv · 发表于：Reviews in Cardiovascular Medicine · 年份：2023 · DOI：10.31083/j.rcm2411335 · 被引用次数：7 · 研究领域：Atrial Fibrillation Management and Outcomes、Coronary Interventions and Diagnostics、Cardiovascular Disease and Adiposity

Background: Device-related thrombosis (DRT) after successful closure implantation on left atrial appendage (LAA) was considered as a major challenge and optimal strategy on antithrombotic therapy remains to be solved. This study was performed to compare the clinical effectiveness and safety of reduced rivaroxaban dose (RRD) and dual antiplatelet therapy (DAPT) after left atrial appendage closure (LAAC) implantation with the Watchman device. Methods: After successful LAAC, consecutive participants were medicated with a standard DAPT or RRD. The primary endpoints included DRT, thrombosis events (TE), and bleeding events that were documented during a 12-month follow-up period. Results: 767 patients (DAPT: n = 140; RRD: n = 627) were initially included. After propensity score matching (PSM), 140 patients treated with DAPT and 280 patients with RRD were included in each group with similar baseline information, thromboembolic and bleeding risk factors, cardiovascular risk factors and concomitant medication. In the RRD group, 193 patients were on rivaroxaban 15 mg (R15) and 47 received rivaroxaban 10 mg (R10). The incidence of DRT was documented in 12 (9.3%) patients in the DAPT group and 3 (6.3%) in R10 and 7 (3.0%) in R15 (log-rank p = 0.050). DAPT subgroups were more likely to experience shorter time to DRT as compared to R15 (R15 vs. DAPT hazard ratio (HR) = 0.334, p = 0.015, 95% CI: 0.131–0.850). The median length of DRT in the R15 group was significantly lower than that of the...